Wistar Institute
A Wistar Institute team found that two hypomorphic p53 variants in separate domains of that gene generate a shared gene expression signature in certain African populations.
Wistar Institute Spinout Isoma Diagnostics Secures Seed Funding
Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
Genetic, Genomic Profiles Point to Potential Utility of Melanoma Xenograft Collection
Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes.
The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.
OncoCyte is proceeding full-steam ahead on commercializing the gene expression-based test, pursuing CLIA certification and a Q2 2017 launch.